Our Services
Medical Information
Helpful Resources
Published on: 9/14/2026
Yes, persistent diarrhea from Wegovy (semaglutide) can lead to dehydration, and in some cases that fluid loss can strain the kidneys, causing acute kidney injury, especially in people taking diuretics, ACE inhibitors, ARBs, or NSAIDs. Warning signs include dark urine, urinating far less than usual, dizziness when standing, rapid heartbeat, extreme thirst, confusion, or swelling in the legs. Several factors affect your personal risk, including how long the diarrhea lasts, your dose, other medications, and existing kidney or heart conditions, so see below to understand more before deciding whether to continue, pause, or adjust treatment.
Because dehydration and kidney injury can progress quietly before symptoms feel serious, it helps to get a structured read on what your specific symptoms suggest. A free, instant, online symptom check can help you sort ordinary GI side effects from red flags that warrant same-day care, and give you clear next steps and questions to bring to your prescriber.
Last reviewed for medical accuracy: 09/14/2026
Wegovy (semaglutide) is a prescription medication approved for weight management. Like many GLP-1 receptor agonists, it can cause gastrointestinal side effects, including diarrhea. If diarrhea from Wegovy keeps happening, you might wonder whether it could lead to dehydration or even kidney damage. This article explains:
Everything here is based on credible sources such as the Wegovy prescribing information, clinical trial data, and expert guidelines.
Understanding the root of the problem helps you tackle it. Here’s why semaglutide (Wegovy) often leads to diarrhea:
Clinical trials report diarrhea in up to 13–18% of Wegovy users. Most cases are mild to moderate and improve over time or after adjusting the dose.
Yes. Ongoing diarrhea leads to water and electrolyte loss. Your body depends on a delicate balance of fluids and minerals (sodium, potassium) to function. If large volumes of stool pass through your intestines:
Signs of dehydration to watch for:
In mild cases, drinking extra water and replacing electrolytes with low-sugar sports drinks or oral rehydration solutions often helps. If you notice warning signs—especially dizziness when standing or very little urine output—contact your healthcare provider right away.
Dehydration stresses all organ systems, including your kidneys. Here’s how:
Reduced blood flow to the kidneys
With less fluid circulating, blood pressure can drop. The kidneys receive less oxygenated blood, leading to prerenal acute kidney injury.
Concentrated waste products
With low fluid volume, your kidneys concentrate toxins and waste, which can harm delicate kidney tissues if prolonged.
Electrolyte imbalances
Low potassium or sodium can disrupt normal kidney cell function, affecting filtration and fluid regulation.
Most people recover fully once hydration is restored. However, if severe dehydration persists, it may trigger:
If you have a history of kidney disease, high blood pressure, or diabetes, you’re at higher risk. Always monitor fluid intake and report concerning symptoms to your doctor.
Before considering stopping Wegovy, try these practical steps:
Hydration strategies
Dietary adjustments
Medication timing and dose
Probiotics
Over-the-counter remedies
Regular follow-up with your healthcare team ensures any adjustments to your regimen are safe.
Persistent or severe diarrhea requires prompt attention. Consider immediate medical care if you experience:
For a quick, preliminary assessment, you might try a free, online symptom check, using the doctor approved Ubie Symptom Checker. This tool can help you understand potential causes and guide you on next steps before talking to a healthcare professional.
Always speak to a doctor about anything that could be life-threatening or serious.
Wegovy can produce meaningful weight loss and improve metabolic health, but gastrointestinal side effects are common, especially early on. The key is:
By staying proactive—hydrating, adjusting your diet, and communicating with your healthcare team—you can minimize risks while enjoying the therapy’s benefits.
Remember, if diarrhea from Wegovy keeps happening or you experience any warning signs of dehydration or kidney stress, reach out for medical support right away. Speak to a doctor about any serious or life-threatening symptoms. Your health and safety always come first.
(References)
* Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, McGowan BM, Rosenstock J, Tran MTD, Wadden TA, Wharton S, Yokote K, Zeuthen N, Kushner RF, STEP 1 Study Group. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021 Mar 18;384(11):989-1002. doi: 10.1056/NEJMoa2032183. Epub 2021 Feb 10. PMID: 33567185.
* Frías JP, Davies MJ, Rosenstock J, Pérez Manghi FC, Fernández Landó L, Bergman BK, Liu B, Cui X, Brown K, SURPASS-2 Investigators. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. N Engl J Med. 2021 Aug 5;385(6):503-515. doi: 10.1056/NEJMoa2107519. Epub 2021 Jun 25. PMID: 34170647.
* Smits MM, Van Raalte DH. Safety of Semaglutide. Front Endocrinol (Lausanne). 2021;12:645563. doi: 10.3389/fendo.2021.645563. Epub 2021 Jul 7. PMID: 34305810; PMCID: PMC8294388.
* Long B, Pelletier J, Koyfman A, Bridwell RE. GLP-1 agonists: A review for emergency clinicians. Am J Emerg Med. 2024 Apr;78:89-94. doi: 10.1016/j.ajem.2024.01.010. Epub 2024 Jan 12. PMID: 38241775.
* Feier CVI, Vonica RC, Faur AM, Streinu DR, Muntean C. Assessment of Thyroid Carcinogenic Risk and Safety Profile of GLP1-RA Semaglutide (Ozempic) Therapy for Diabetes Mellitus and Obesity: A Systematic Literature Review. Int J Mol Sci. 2024 Apr 15;25(8). doi: 10.3390/ijms25084346. Epub 2024 Apr 15. PMID: 38673931; PMCID: PMC11050669.
* Gudzune KA, Kushner RF. Medications for Obesity: A Review. JAMA. 2024 Aug 20;332(7):571-584. doi: 10.1001/jama.2024.10816. PMID: 39037780.
* Kelly AS, Armstrong SC, Michalsky MP, Fox CK. Obesity in Adolescents: A Review. JAMA. 2024 Sep 3;332(9):738-748. doi: 10.1001/jama.2024.11809. PMID: 39102244.
* Begum F, Chang K, Kapoor K, Vij R, Phadke G, Hiser WM, Wanchoo R, Sharma P, Sutaria N, Jhaveri KD. Semaglutide-associated kidney injury. Clin Kidney J. 2024 Sep;17(9):sfae250. doi: 10.1093/ckj/sfae250. Epub 2024 Aug 13. PMID: 39258261; PMCID: PMC11384876.
* Moiz A, Filion KB, Toutounchi H, Tsoukas MA, Yu OHY, Peters TM, Eisenberg MJ. Efficacy and Safety of Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss Among Adults Without Diabetes : A Systematic Review of Randomized Controlled Trials. Ann Intern Med. 2025 Feb;178(2):199-217. doi: 10.7326/ANNALS-24-01590. Epub 2025 Jan 7. PMID: 39761578.
* Garvey WT, Blüher M, Osorto Contreras CK, Davies MJ, Winning Lehmann E, Pietiläinen KH, Rubino D, Sbraccia P, Wadden T, Zeuthen N, Wilding JPH, REDEFINE 1 Study Group. Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2025 Aug 14;393(7):635-647. doi: 10.1056/NEJMoa2502081. Epub 2025 Jun 22. PMID: 40544433.
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.